ovlpaw8\□□\8888888

OncoImmunology

ISSN: (Print) 2162-402X (Online) Journal homepage: http://www.tandfonline.com/loi/koni20

Molecular and clinical characterization of TIM-3 in glioma through 1,024 samplesM□ndatglLOzlLrglL□L□q□□a□□□ac

Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=koni20

Download by: [Capital Medical University] **Date:** 18 December 2017, At: 18:42

murine glioma model. PLoS One 2014; 9(7):e101764; PMID:25013914; https://doi.org/10.1371/journal.pone.0101764
24. Zhang L, Zhang Z, Liu Y, Xue Y, Parney I. Programmed death-ligand 1 (PD-L1) may play a role in malignant glioma tumor progression. Med Hypotheses 2015; 85(2):127-9; PMID:25936667; https://doi.org/10.1016/j.mehy.2015.04.009
25. Wang Z, Yin N, Zhang Z, Zhang Y, Zhang G, Chen W. Upregulation of T-cell immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in monocytes/macrophages associates with gastric cancer progression. Immunol Invest 2017; 46(2):134-148; PMID:27911104; https://doi.org/10.1080/08820139.2016.1229790
26. Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, Murphy WJ, Azuma M, Anderson AC, Kuchroo VK et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011; 117(17):4501-10; PMID:21385853; https://doi.org/10.1182/blood-2010-10-310425
27. Sakuishi K, Ngiow SF, Sullivan JM, Teng MW, Kuchroo VK, Smyth MJ, Anderson AC. TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology 2013; 2(4):e23849; PMID:23734331; https://doi.org/10.4161/onci.23849
28. Cipolletta D, Feuerer M, Li A, Kamei N, Lee J, Shoelson SE, Benoist C, Mathis D. PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 2012; 486(7404):549-53; PMID:22722857; https://doi.org/10.1038/nature11132
29. Burzyn D, Kuswanto W, Kolodin D, Shadrach JL, Cerletti M, Jang Y, Sefik E, Tan TG, Wagers AJ, Benoist C et al. A special population of regulatory T cells potentiates muscle repair. Cell 2013; 155(6):1282-95; PMID:24315098; https://doi.org/10.1016/j.cell.2013.10.054
30. Rangachari M, Zhu C, Sakuishi K, Xiao S, Karman J, Chen A, Angin M, Wakeham A, Greenfield EA, Sobel RA et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion. Nat Med 2012; 18(9):1394-400; PMID:22863785; https://doi.org/10.1038/nm.2871
31. Zhang Y, Ma CJ, Wang JM, Ji XJ, Wu XY, Moorman JP, Yao ZQ. Tim-3 regulates pro- and anti-inflammatory cytokine expression in human CD14+ monocytes. J Leukoc Biol 2012; 91(2):189-96; PMID:21844165; https://doi.org/10.1189/jlb.1010591
32. Ramello MC, Tosello BJ, Canale FP, Mena HA, Negrotto S, Gastman B, Gruppi A, Acosta Rodriguez EV, Montes CL. Tumor-induced senescent T cells promote the secretion of pro-inflammatory cytokines and angiogenic factors by human monocytes/macrophages through a mechanism that involves Tim-3 and CD40L. Cell Death Dis 2014; 5: e1507; PMID:25375372; https://doi.org/10.1038/cddis.2014.451
33. Wang S, Cao C, Piao H, Li Y, Tao Y, Zhang X, Zhang D, Sun C, Zhu R, Wang Y et al. Tim-3 protects decidual stromal cells from toll-like receptor-mediated apoptosis and inflammatory reactions and promotes Th2 bias at the maternal-fetal interface. Sci Rep 2015; 5:9013; PMID:25757669; https://doi.org/10.1038/srep09013
34. Li X, Chen G, Li Y, Wang R, Wang L, Lin Z, Gao X, Feng J, Ma Y, Shen B et al. Involvement of T cell Ig Mucin-3 (Tim-3) in the negative regulation of inflammatory bowel disease. Clin Immunol 2010; 134(2):169-77; PMID:19913460; https://doi.org/10.1016/j.clim.2009.09.012
35. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010; 207 (10):2175-86; PMID:20819923; https://doi.org/10.1084/jem.20100637
36. Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, Sun J, Yang Q, Zhang X, Lu B. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One 2012; 7(2):e30676; PMID:22363469; https://doi.org/10.1371/journal.pone.0030676
37. Kim JE, Patel MA, Mangraviti A, Kim ES, Theodros D, Velarde E, Liu A, Sankey EW, Tam A, Xu H et al. Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. Clin Cancer Res 2017; 23(1):124-136; PMID:27358487; https://doi.org/10.1158/1078-0432.CCR-15-1535
38. Kikushige Y, Shima T, Takayanagi S, Urata S, Miyamoto T, Iwasaki H, Takenaka K, Teshima T, Tanaka T, Inagaki Y et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 2010; 7(6):708-17; PMID:21112565; https://doi.org/10.1016/j.stem.2010.11.014

Downloaded by [Capital Medical University] at 18:42 18 December 2017